Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
-
A8704 StiripentolTarget: Lactate Dehydrogenases (LDH)Summary: An LDH inhibitor
-
A8703 IsosafroleTarget: Lactate Dehydrogenases (LDH)Summary: A stiripentol analog, a potent LDH inhibitor.
-
A3358 DeltarasinTarget: Phosphodiesterases (PDEs)Summary: KRAS-PDEδ interaction inhibitor
-
A3374 DronedaroneTarget: Cytochrome P450 (CYP450)|sodium channel|adrenergic receptor|potassium channel|calcium channelSummary: CYP3A4 and 2D6 inhibitor,moderate
-
A3419 FluvastatinTarget: HMGCRSummary: HMGCR inhibitor
-
A3453 GW1929Target: PPARSummary: Potent PPARγ agonist
-
A3493 INCB024360 analogueSummary: potent and selective inhibitor of IDO1
-
A3536 L-165041Target: PPARSummary: PPARβ/δ agonist,cell permeable,potent and selective
-
A3552 Levomefolate calciumSummary: Artificial form of folate
-
A3565 LX-1031Target: Tryptophan hydroxylases (TPH)Summary: TPH inhibitor